Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03455309|
Recruitment Status : Completed
First Posted : March 6, 2018
Last Update Posted : January 29, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Staphylococcus Aureus||Biological: NDV-3A Biological: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||382 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||double-blind, placebo-controlled, randomized study|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Sponsor, principal investigator and study site are all blinded but can access key if safety issues require unblinding|
|Official Title:||A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization|
|Actual Study Start Date :||January 30, 2018|
|Actual Primary Completion Date :||July 19, 2019|
|Actual Study Completion Date :||October 15, 2019|
Active Comparator: NDV-3A
0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
Single dose administered by intramuscular injection
Placebo Comparator: Placebo
0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
Single dose administered by intramuscular injection
- Prevent acquisition of incident Staphylococcus aureus nasal colonization [ Time Frame: 56 days post-vaccination ]Change in incident Staphylococcus aureus nasal colonization by study day 56 in a population of US Army trainees at Ft. Benning, GA
- Evaluation of the efficacy of the NDV-3A vaccine [ Time Frame: 0-90 days ]Describe SSTI rates within the training company as defined by the development of skin and soft tissue infection (SSTI) over the training period as compared to other companies in the battalion as well as historical data
- Evaluation of the efficacy of the NDV-3A vaccine [ Time Frame: 0-90 days ]Describe NDV-3A-associated delay in time to first nasal acquisition of S. aureus colonization
- Evaluation of the efficacy of the NDV-3A vaccine [ Time Frame: 0-90 days ]Describe reduction in cross-sectional prevalence of S. aureus nasal/oral colonization
- Evaluation of safety and tolerability in all subjects [ Time Frame: 0-7 days ]Occurrence of solicited adverse events (AE) over a 7-day follow-up period following vaccination
- Evaluation of safety and tolerability in all subjects [ Time Frame: 0-28 days ]Occurrence of unsolicited AEs over a 28-day follow-up period following vaccination
- Evaluation of safety and tolerability in all subjects [ Time Frame: 0-90 days ]Occurrence of serious adverse events (SAE) or Adverse Events of Special Interest (AESI) at any time during the study period (enrollment to final in-person follow-up visit)
- Measurement and characterization of immunogenicity of NDV-3A [ Time Frame: 0-90 days ]Describe the humoral immune response induced by NDV-3A using ELISA analysis of serum
- Measurement and characterization of immunogenicity of NDV-3A [ Time Frame: 0-14 days ]Describe the cell mediated immune responses induced by NDV-3A using ELISpot analysis of PBMCs
- Describe the impact of NDV-3A on S. aureus acquisition and transmission [ Time Frame: 0-90 days ]Following determination of taxonomy (via sequencing of 16S rRNA), determine the relative abundance and distribution of, and change in, bacterial species colonizing the nose and throat (i.e. nasal/oral microbiome) of military trainees during the training period.
- Describe the impact of NDV-3A on S. aureus acquisition and transmission [ Time Frame: 0-90 days ]Compare the compositions of the nasal/oral microbiome between study groups to assess the impact of NDV-3A vaccine on the nasal/oral microbiome.
- Describe the impact of NDV-3A on S. aureus acquisition and transmission [ Time Frame: 0-90 days ]Utilize a combination of epidemiologic, microbiologic, and genomic data on colonization isolates to describe the intra-class transmission dynamics of S. aureus among congregate military trainees
- Describe the impact of NDV-3A on S. aureus acquisition and transmission [ Time Frame: 0-90 days ]Conduct whole genome sequencing on isolates to describe the intra- and inter-host concordance of infecting and colonizing strains of S. aureus
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||17 Years to 35 Years (Child, Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||Yes|
- Active duty, male subject, 17-35 years of age, inclusive, at the time of screening.
- Assigned to one of the selected companies/battalions
- Informed of the nature of the study and has agreed to and is able to read, review, and sign the informed consent document prior to screening.
- Free of known significant health problems as established by the requirements to be enrolled in a military training program before entering into the study.
- Agrees to be reachable by phone, email or letter at 6 months post-vaccination.
- Reports receiving any investigational drug, investigational vaccine, or investigational device within 30 days prior to dosing; subjects will be allowed to receive routine vaccinations associated with training and any other prescribed medications not in the exclusion criteria.
- Presence of clinically significant SSTI (e.g., cellulitis, abscess) at screening or other skin or skin structure infections that would confound the interpretation of clinical response.
- Reports a history of allergic response(s), anaphylaxis, or other serious reactions to previous vaccinations.
- Reports a history of allergies to yeast
- Reports a history of anaphylaxis or other serious reactions to aluminum.
- Reports a history of autoimmune disease (psoriasis, etc.)
- Seropositive for HIV antibody.
- Reports the use of any immunosuppressive drugs, including systemic corticosteroids (more than 14 days at a dose of >20 mg/day prednisone or equivalent), within 4 weeks prior to dosing.
- Reports receiving any blood products within 3 months prior to dosing.
- Reports donating blood/plasma within 28 days prior to dosing.
- Illness causing temperature ≥ 100.4°F
- Evidence of abnormal, unresolved laboratory results in the subject's medical record for the following tests: hemoglobin, white blood cell count, platelet count, creatinine, and alanine aminotransferase
- Any other medical and/or social reason which, in the opinion of the investigator(s), would increase the subject's risk of having an adverse reaction as a result of participation in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03455309
|United States, Georgia|
|Fort Benning, Georgia, United States, 31905|
|Principal Investigator:||Jason W Bennett, MD||USU IDCRP|
|Responsible Party:||NovaDigm Therapeutics, Inc.|
|Other Study ID Numbers:||
IDCRP-104 ( Other Identifier: IDCRP, USU )
|First Posted:||March 6, 2018 Key Record Dates|
|Last Update Posted:||January 29, 2020|
|Last Verified:||January 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
incident nasal colonization